Advertisement

A Preclinical and Clinical Overview of the Nucleotide-Based Antiviral Agent Cidofovir (HPMPC)

  • Jacob P. Lalezari
  • Robert J. Stagg
  • Howard S. Jaffe
  • Michael J. M. Hitchcock
  • W. Lawrence Drew
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 394)

Abstract

Cidofovir, formerly known as HPMPC, is a nucleotide analog with potent activity against a broad spectrum of herpesviruses, including important human pathogens such as cytomegalovirus (CMV), herpes simplex virus types 1 and 2 (HSV-1, HSV-2), varicella-zoster virus (VZV), and Epstein-Barr virus (EBV).1–3 Cidofovir is a phosphonomethylether derivative of the nucleotide, cytosine monophosphate (Figure 1).

Keywords

Cynomolgus Monkey Simian Varicella Virus Oral Probenecid Proximal Convoluted Tubule Cell Sulfa Allergy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    De Clercq E, Sakuma T, Baba M, et al. Antiviral activity of phosphonylmethoxyalkyl derivatives of purines and pyrimidines. Antiviral Res 8: 261–272, 1987.PubMedCrossRefGoogle Scholar
  2. 2.
    Bronson J J, Ghazzouli I, Hitchcock M J M, Webb II R R and Martin J C. Synthesis and antiviral activity of the nucleotide analogue (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine. J Med Chem 32: 1457–1463, 1989.PubMedCrossRefGoogle Scholar
  3. 3.
    Martin J C and Hitchcock M J M. Phosphomethylether compounds as antiviral agents. Trans ProcGoogle Scholar
  4. 4.
    :156–158, 1991.Google Scholar
  5. 5.
    Connelly M, Robbins B, and Fridland A. Mechanism of Uptake of the Phosphonate Analog (S)-1(3Hydroxy-2-phosphonylmethoxy-propyl)cytosine (HPMPC) in Vero Cells. Biochemical Pharmacology 1993, 46: 1043.CrossRefGoogle Scholar
  6. 6.
    Biron K K, Stanet S C, Sorrell J B, et al. Metabolic activation of the nucleoside analog 9.Google Scholar
  7. 7.
    -hydroxy-1-(hydroxymethyl)ethoxy]methylguanine in human diploid fibroblasts infected with humanGoogle Scholar
  8. 8.
    cytomegalovirus. Proc. Nat. Acad. Sci. USA 82: 2473–2477, 1985.CrossRefGoogle Scholar
  9. 9.
    Ho H T, Woods KL, Bronson J J, et al. Intracellular metabolism of the antiherpes agent (S)-1-[3-hydroxy2-(phosphonylmethoxy)propyl]cytosine. Molec. Pharm. 41: 197–202, 1991Google Scholar
  10. 10.
    Li S B, Yang Z-H, Feng J S, et al. Activity of (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propy1]-cytosine (HPMPC) against guinea pig cytomegalovirus infection in cultured cells and in guinea pigs. Antiviral Res. 13: 237–252, 1990.PubMedCrossRefGoogle Scholar
  11. 11.
    Snoeck R, Sakuma T, De Clercq E, Rosenberg I and Holy A. (S)-1-[3-hydroxy-2(phosphonymethoxy)propyl]cytosine, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob. Agents and Chemo. 32: 1839–1844, 1988.CrossRefGoogle Scholar
  12. 12.
    Study DAVI-TJ-21693 “Multiple dose subcutaneous nephrotoxicity study in male guinea pigs ” (Data on file at Gilead Sciences, Inc.)Google Scholar
  13. 13.
    Study DAVI-MH-21596, “BMY-41671 (HPMPC): ”Multiple dose intravenous nephrotoxicity screening study with probenecid in male rabbits.“ (Data on file at Gilead Sciences, Inc.)Google Scholar
  14. 14.
    Study TSI 2-TO1, “Thirteen week repeated dose toxicity study of HPMPC (GS-504) administered intraveously to cynomolgus monkeys in combination with orally administered probenecid.” (Data on file at Gilead Sciences, Inc.)Google Scholar
  15. 15.
    Study TSI 2T70, “Twenty-six week repeat dose study of GS-504 (HPMPC) administered subcutaneously to rats.” (Data on file at Gilead Sceiences, Inc.)Google Scholar
  16. 16.
    Study TSI 2-P50, “Thirteen week repeated dose toxicity study of HPMPC administered intravenously to Sprague-Dawley Rats.” (Data on file at Gilead Sciences, Inc.)Google Scholar
  17. 17.
    Study TSI 2-P51, “Thirteen week repeated dose toxicity study of HPMPC administered intravenously to cynomolgus monkeys.” (Data on file at Gilead Sciences, Inc.)Google Scholar
  18. 18.
    Study 94-DDM-0504–004, “Tissue distribution of 14C-HPMPC (cidofovir) at 6 and 24 hours after single dose administration to female Sprague-Dawley Rats”. (Data on file at Gilead Sciences, Inc.)Google Scholar
  19. 19.
    Kern E R. Value of animal models to evaluate agents with potential activity against human cytomegalovirus. Trans. Proc. 23: 152–155, 1991.Google Scholar
  20. 20.
    Lalezari JP, Drew WL, Glutzer E, et al. Cidofovir (I-IPMPC): Results of a phase I/II studyof a novel antiviral nucelotide analogue. J. Infectious Dis (In Press)Google Scholar
  21. 21.
    Cundy KC. A report on the effect of cidofovir on the pharmacokinetics of AZT - Johns Hopkins Data. (Data on file at Gilead Sciences, Inc.).Google Scholar
  22. 22.
    Abrams D, Goldman A, Launer C, et al. A comparative trial of didanosine and zalcitabine after treatment with zidovudine in patients with human immunodeficincy virus infection. New England J Med 330: 657–662, 1994.CrossRefGoogle Scholar
  23. 23.
    Studies of the Ocular Complications of AIDS (SOCA) database (analysis performed by Gilead Sciences, Inc.).Google Scholar
  24. 24.
    Stavudine (d4T) Investigator’s Brochure, July 1994.Google Scholar
  25. 25.
    Kuppermann B, Lalezari J, Stagg R, et al. A phase I11111 randomised study of immediate versus deferred intravenous cidofovir for AIDS patients with peripheral CMV retinitis. International Symposium on Experimental and Clinical Ocular Pharmacology and Pharmaceutics. 1995 (abstract).Google Scholar
  26. 26.
    Lalezari J, Holland G, Stagg R, et al. A randomized controlled study of cidofovir for relapsing cytomegalovirus retinitis in patients with AIDS. 35th International Conference on Antimicrobial Agents and Chemotherapy, Program Addendum LB-9, 1995 (abstract).Google Scholar

Copyright information

© Springer Science+Business Media New York 1996

Authors and Affiliations

  • Jacob P. Lalezari
  • Robert J. Stagg
  • Howard S. Jaffe
  • Michael J. M. Hitchcock
  • W. Lawrence Drew

There are no affiliations available

Personalised recommendations